{
    "nct_id": "NCT04697576",
    "official_title": "Intralesional Influenza Vaccine for Patients with Melanoma",
    "inclusion_criteria": "* 18 to 99 years of age\n* Histologically confirmed cutaneous melanoma by historical pathology report review, clinical Stage I-III (Cohort #1), or Stage IV (Cohort #2) cutaneous melanoma\n* At least one, biopsy-proven, palpable melanoma tumor deposit suitable for intralesional injection measuring â‰¥ 1 cm by digital caliper (with digital photography documentation) or ultrasound (with ultrasound image documentation)\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Known allergy or intolerance to influenza vaccination\n* Subjects with condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone/equivalent) or other immunosuppressive medications within 14 days of study drug administration\n* Active, known or suspected autoimmune disease\n* Active brain metastasis or leptomeningeal metastasis\n* Diagnostic biopsy of ocular or mucosal melanoma\n* Any melanoma therapy within 6 months of enrollment; though prior surgical resection is permitted\n* Incarcerated patients\n* Human immunodeficiency virus (HIV) positive patients\n* Pregnant or lactating patients\n* Patients incapable of independently providing consent",
    "miscellaneous_criteria": ""
}